Relationship between diagnosis delay and disease features in Moroccan patients with ankylosing spondylitis

被引:0
作者
Yousra Ibn Yacoub
Bouchra Amine
Assia Laatiris
Rachida Bensabbah
Najia Hajjaj-Hassouni
机构
[1] University Hospital of Rabat-Sale,Department of Rheumatology (Pr N. Hajjaj
来源
Rheumatology International | 2012年 / 32卷
关键词
Diagnosis delay; Ankylosing spondylitis; Function; Activity; Mobility; Radiographic damage;
D O I
暂无
中图分类号
学科分类号
摘要
We aimed to evaluate diagnosis delay and its impact on disease in terms of activity, functional disability, and radiographic damage in Moroccan patients with ankylosing spondylitis (AS). We recruited 100 Moroccan patients who fulfilled New York Classification criteria for AS. Diagnosis delay was defined as the interval between the first symptom of AS and the moment of a correct diagnosis. Disease activity was evaluated by the bath ankylosing spondylitis disease activity index (BASDAI), functional status by the bath ankylosing spondylitis functional index (BASFI), and radiographic damage by the bath ankylosing spondylitis radiologic index (BASRI). Measurements of spinal mobility were assessed. The average age at disease onset was 28.56 ± 10.9 years. Of the patients, 16% had juvenile-onset AS. Disease duration was 9.5 ± 6.8 years, and the average of diagnosis delay was 4.12 ± 3.99 years. There were no differences in diagnosis delay according to the age at onset, educational level, or the presence of extra-articular involvement. Our patients had altered functional ability. Patients with late diagnosis (>5 years) had statistically significant higher structural damage (BASRI) and severe limited spinal mobility. There was no correlation between diagnosis delay and the activity of disease. Few studies focused on diagnostic delay and its impact in patients with AS. It is necessary in our context to establish an early diagnosis taking into account the high frequency of severe functional disability in Moroccan AS.
引用
收藏
页码:357 / 360
页数:3
相关论文
共 73 条
[1]  
Dincer U(2008)Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria Clin Rheumatol 27 457-462
[2]  
Cakar E(2002)Ankylosing spondylitis: introductory comments on its diagnosis and treatment Ann Rheum Dis 61 3-7
[3]  
Kiralp MZ(2006)Definition of disease duration in ankylosing spondylitis: reassessing the concept Ann Rheum Dis 65 1518-1520
[4]  
Dursun H(2002)Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy Arthritis Rheum 46 755-765
[5]  
Khan MA(2003)Grassnickel Letal. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis Arthritis Rheum 48 1667-1675
[6]  
Davis JC(2009)Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes–an Indian perspective Clin Rheumatol 28 327-331
[7]  
Dougados M(2009)Two distinct patterns of ankylosing spondylitis in Moroccan patients Rheumatol Int 29 1423-1429
[8]  
Braun J(1987)New criteria for the diagnosis of ankylosing spondylitis Scand J Rheumatol Suppl 65 12-24
[9]  
Sieper J(2004)Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness Rheumatol 43 750-757
[10]  
van der Heijde D(2006)The relationship between severity and extent of spinal involvement and spinal mobility and physical functioning in patients with ankylosing spondylitis Clin Rheumatol 25 835-839